When UCSF's Charles Chiu was tapped by the CDC to sequence viral strains from throughout California, he knew he needed more capacity.
With the help of Illumina NextSeq 550 and reagents, Dr. Bedford was able to identify one of the first COVID-19 clusters in the US.
Illumina has developed two workflows to detect and track SARS-CoV-2 from clinical samples.
NGS has the unique ability to support scientists, researchers, public health officials and health care professionals on the front lines. It helps us understand transmission routes, comorbidities, and mutation rates, serves as a foundation for vaccine development and therapies, and ultimately helps predict and prevent future outbreaks.Learn More from CMO Phil Febbo
We believe access to the best technologies, global networks, and genomic insights are crucial to stop this pandemic and keep it from coming back. This is why we work with researchers, the CDC, the Chinese CDC, the NIH, GISAID, Stanford, the Broad Institute, and more to make sure they have the support they need to succeed.Read COVID-19 Stories
We are a global company championing the greater good, committed to supporting COVID-19 efforts around the world. We are proud to partner to fund the Africa Centre of Excellence for Genomics of Infectious Diseases as well as the Milken Institute to develop global surveillance networks.
With our decades of experience, vast global reach, support across countries and languages, as well as data transparency, we are afforded a humbling opportunity to quickly connect and support local and global resources to fight this pandemic across the world.
Allows researchers to identify novel pathogens and helps accelerate outbreak investigations.
Detects SARS-CoV-2 as well as common respiratory pathogens, and provides information about epidemiology and evolution.
This high-throughput NGS test detects RNA from the SARS-CoV-2 virus.